Everest Clinical Research Expands Global Reach with the Acquisition of August Research

Everest Clinical Research, a leading contract research organization (CRO), has announced its acquisition of August Research, a European CRO specializing in Clinical Trial Services (CTS) and Pharmacovigilance (PV). The acquisition marks Everest's expansion into the European market, allowing the company to offer full-service CTS solutions to its global client base.

August Research has an impressive portfolio of over 120 projects for Phase I-IV clinical trials in various therapeutic areas, including cardiovascular, infectious disease, oncology, and rare diseases. With offices in 14 countries across Western and Eastern Europe, August brings a wealth of experience and infrastructure to Everest's operations.

The founders of August, Dana Leff Niedzielska and Lukasz Niedzielski, along with other managing directors, will continue to lead the business post-transaction. Their expertise in clinical research and strong client-focused culture align well with Everest's values, making this acquisition a strategic move for both companies.

This acquisition holds immense strategic significance for Everest Clinical Research. It not only expands the company's global service offering but also establishes a strong presence in one of the largest clinical trial markets in the world. By adding European offices to its existing presence in North America and Asia, Everest solidifies its position as a truly global CRO.

Jin Dai, the COO of Everest, expressed enthusiasm for the partnership, stating that August's leading European clinical operations capabilities will be introduced to Everest's US customer base. This collaboration aims to build a comprehensive and quality-focused biometrics and data management practice in Europe.

The merger of Everest and August Research creates a powerhouse in the CRO industry. While Everest is known for its top-tier clinical trial data and analytical services, Interactive Response Technologies, pharmacovigilance, medical writing, and North American clinical operations services, August brings deep European clinical operations, regulatory expertise, and local pharmacovigilance capabilities to the table. This synergy will enable the merged company to provide a full suite of clinical services on a global scale, opening doors to accelerated growth opportunities.

Everest Clinical Research Corporation is a full-service CRO offering a wide range of expertise-based clinical research services to the pharmaceutical, biotechnology, and medical device industries worldwide. With headquarters in Toronto, Canada, and additional offices in the United States, China, and Taiwan, Everest has built a reputation for delivering high-quality results, superior customer service, and flexibility in meeting clients' needs.

Arlington Capital Partners, a Washington, DC-based private equity firm, is the owner of Everest Clinical Research. With approximately $7 billion in capital commitments, Arlington focuses on middle-market investment opportunities in growth industries such as healthcare, government services and technology, aerospace & defense, and business services and software. Arlington's partnership with Everest positions the company as a leading competitor in the field, leveraging their combined industry knowledge and experience.

In conclusion, Everest Clinical Research's acquisition of August Research marks an important step in the company's growth strategy. By expanding into the European market, Everest will strengthen its position as a global leader in the CRO industry. The merger of these two reputable organizations brings together a wealth of expertise, capabilities, and resources, creating new opportunities for advancing life-changing research worldwide.